CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 141 enrolled
Drug / intervention
Peginterferon alfa-2abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01667432
NCT01667432N/ACompleted
CompareCT.gov

A Multicenter, Prospective, Observational, Non-interventional Study Evaluating On-treatment Predictors of Response in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD)

Hoffmann-La Roche·observational·Posted Aug 17, 2012·Updated Apr 10, 2017

In Brief

An observational study evaluating Peginterferon alfa-2a for Hepatitis B, Chronic. Completed, enrolled 141 participants across 9 sites.

Detailed Summary

This prospective, multicenter, observational study will evaluate on-treatment predictors of response in patients with HBeAg positive or HBeAg negative chronic hepatitis B receiving treatment with peginterferon alfa-2a (PEGASYS®) in accordance with local labeling and the summary of product characteristics. Data will be collected from patients for the duration of their treatment and for up to 24 weeks thereafter.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesBulgaria
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2012
Enrollment StartJul 8, 2011
Primary CompletionAug 12, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 13.9 years ago

Interventions

Peginterferon alfa-2abiological

Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.